Figure 4. PGH₁ activates human eosinophils via CRTH2.

Human eosinophils were treated with the indicated concentrations of PGD₂, PGH₁, and PGH₂, respectively, and chemotactic activation was measured in eosinophil shape change assays. Eosinophil shape change is inhibited in the presence of 1 µM of the CRTH2-specific antagonist TM30089. Note: rank order of PG potency matches well with the results obtained in CRTH2-HEK transfectants using DMR assays (compare with Figure 1F ). Results are expressed as the mean ± SEM of 3 experiments conducted in triplicate with a separate donor used in each experiment. Statistical analysis was performed for vehicle vs. TM30089 treated cells and is indicated as (**) for p<0.01 and as (***) for p<0.001.